O Sitbon, F Brenot, A Denjean, A Bergeron, F Parent, R Azarian, P Herve, B Raffestin and G Simonneau
Service de Pneumologie et Reanimation, Hopital Antoine Beclere, Clamart, France.

To investigate the capacity of the pulmonary vascular bed to acutely vasodilate, we examined in 35 consecutive patients with primary pulmonary hypertension (PPH), the hemodynamic effects of incremental inhalation periods of an air-NO mixture at different concentrations (10, 20, and 40 ppm), and compared them with those of an acute infusion of prostacyclin (PGI2). An individual pulmonary vasodilator response was defined by a fall in total pulmonary resistance (TPR) > or = 30% relative to mean TPR baseline value. Thirteen patients were responders and 22 were nonresponders to both drugs, and they did not significantly differ in overall baseline characteristics except for mean right atrial pressure (p < 0.03). In responders, both drugs produced similar individual vasodilator response. Changes in mean pulmonary arterial pressure and TPR observed during NO and PGI2 were closely correlated (r2 = 0.9, p < 0.001, and r2 = 0.7, p < 0.01, respectively). The vasodilator response to NO was not concentration-related with a maximal effect obtained at 10 ppm. Combination of both drugs did not lead to any additive vasodilator response. Unlike PGI2, NO did not induce any systemic effect, no adverse reaction, but a moderate increase in methemoglobin. Inhaled NO at low dose (10 ppm) appears to be an effective, safe, and reliable substitute for PGI2 in screening for acute pulmonary vasodilator responsiveness during therapeutic assessment of patients with PPH.

This article has been cited by other articles:

				M. P. Coggins and K. D. Bloch Nitric Oxide in the Pulmonary Vasculature Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1877 - 1885. [Abstract] [Full Text] [PDF]

				J. D. Edelman Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 110 - 118. [Abstract] [PDF]

				H.-H. Hsu, J.-S. Chen, Y.-S. Chen, W.-J. Ko, S.-W. Kuo, and Y.-C. Lee Short-term intravenous iloprost for treatment of reperfusion lung oedema after pulmonary thromboendarterectomy Thorax, May 1, 2007; 62(5): 459 - 461. [Abstract] [Full Text] [PDF]

				C. Jardim, C. E. Rochitte, M. Humbert, G. Rubenfeld, D. Jasinowodolinski, C. R. R. Carvalho, and R. Souza Pulmonary artery distensibility in pulmonary arterial hypertension: an MRI pilot study Eur. Respir. J., March 1, 2007; 29(3): 476 - 481. [Abstract] [Full Text] [PDF]

				I. George, S. Xydas, V. K. Topkara, C. Ferdinando, E. C. Barnwell, L. Gableman, R. N. Sladen, Y. Naka, and M. C. Oz Clinical Indication for Use and Outcomes After Inhaled Nitric Oxide Therapy Ann. Thorac. Surg., December 1, 2006; 82(6): 2161 - 2169. [Abstract] [Full Text] [PDF]

				D J Fox and R S Khattar Pulmonary arterial hypertension: classification, diagnosis and contemporary management Postgrad. Med. J., November 1, 2006; 82(973): 717 - 722. [Full Text] [PDF]

				S. Ulrich, M. Fischler, R. Speich, V. Popov, and M. Maggiorini Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest, September 1, 2006; 130(3): 841 - 846. [Abstract] [Full Text] [PDF]

				C. G. Elliott, E. W. Glissmeyer, G. T. Havlena, J. Carlquist, J. T. McKinney, S. Rich, M. D. McGoon, M. B. Scholand, M. Kim, R. L. Jensen, et al. Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension Circulation, May 30, 2006; 113(21): 2509 - 2515. [Abstract] [Full Text] [PDF]

				S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jais, and G. Simonneau Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension Eur. Heart J., March 1, 2006; 27(5): 589 - 595. [Abstract] [Full Text] [PDF]

				S. Provencher, D. Chemla, P. Herve, O. Sitbon, M. Humbert, and G. Simonneau Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension Eur. Respir. J., January 1, 2006; 27(1): 114 - 120. [Abstract] [Full Text] [PDF]

				M. J.D. Griffiths and T. W. Evans Inhaled Nitric Oxide Therapy in Adults N. Engl. J. Med., December 22, 2005; 353(25): 2683 - 2695. [Full Text] [PDF]

				L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]

				T Kuehne, S Yilmaz, I Schulze-Neick, E Wellnhofer, P Ewert, E Nagel, and P Lange Magnetic resonance imaging guided catheterisation for assessment of pulmonary vascular resistance: in vivo validation and clinical application in patients with pulmonary hypertension Heart, August 1, 2005; 91(8): 1064 - 1069. [Abstract] [Full Text] [PDF]

				O. Sitbon, M. Humbert, X. Jais, V. Ioos, A. M. Hamid, S. Provencher, G. Garcia, F. Parent, P. Herve, and G. Simonneau Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension Circulation, June 14, 2005; 111(23): 3105 - 3111. [Abstract] [Full Text] [PDF]

				R. Rodriguez-Roisin, M.J. Krowka, Ph. Herve, M.B. Fallon, and on behalf of the ERS Task Force Pulmonary-Hepatic Pulmonary-Hepatic vascular Disorders (PHD) Eur. Respir. J., November 1, 2004; 24(5): 861 - 880. [Full Text] [PDF]

				H. A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Olschewski, P. Haredza, B. Karadas, R. T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1488 - 1496. [Abstract] [Full Text] [PDF]

				M.C. Post, S. Janssens, F. Van de Werf, and W. Budts Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension Eur. Heart J., September 2, 2004; 25(18): 1651 - 1656. [Abstract] [Full Text] [PDF]

				B. M. Tsai, M. Wang, M. W. Turrentine, Y. Mahomed, J. W. Brown, and D. R. Meldrum Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies Ann. Thorac. Surg., July 1, 2004; 78(1): 360 - 368. [Abstract] [Full Text] [PDF]

				D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]

				S. Huez, S. Brimioulle, R. Naeije, and J.-L. Vachiery Feasibility of Routine Pulmonary Arterial Impedance Measurements in Pulmonary Hypertension Chest, June 1, 2004; 125(6): 2121 - 2128. [Abstract] [Full Text] [PDF]

				H.A. Ghofrani, G. Friese, T. Discher, H. Olschewski, R.T. Schermuly, N. Weissmann, W. Seeger, F. Grimminger, and J. Lohmeyer Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension Eur. Respir. J., February 1, 2004; 23(2): 321 - 326. [Abstract] [Full Text] [PDF]

				H. H. Leuchte, M. Schwaiblmair, R. A. Baumgartner, C. F. Neurohr, T. Kolbe, and J. Behr Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension Chest, February 1, 2004; 125(2): 580 - 586. [Abstract] [Full Text] [PDF]

				P. Wauthy, S. Abdel Kafi, W. J. Mooi, R. Naeije, and S. Brimioulle Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1434 - 1441. [Abstract] [Full Text] [PDF]

				H. Olschewski, B. Rohde, J. Behr, R. Ewert, T. Gessler, H. A. Ghofrani, and T. Schmehl Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension Chest, October 1, 2003; 124(4): 1294 - 1304. [Abstract] [Full Text] [PDF]

				H. A. Ghofrani, F. Rose, R. T. Schermuly, H. Olschewski, R. Wiedemann, A. Kreckel, N. Weissmann, S. Ghofrani, B. Enke, W. Seeger, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J. Am. Coll. Cardiol., July 2, 2003; 42(1): 158 - 164. [Abstract] [Full Text] [PDF]

				A. Sablotzki, E. Czeslick, E. Gruenig, I. Friedrich, S. Schubert, J. Borgermann, and T. Hentschel First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance J. Thorac. Cardiovasc. Surg., April 1, 2003; 125(4): 960 - 962. [Full Text] [PDF]

				K Vonbank, R Ziesche, T W Higenbottam, L Stiebellehner, V Petkov, P Schenk, P Germann, and L H Block Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD Thorax, April 1, 2003; 58(4): 289 - 293. [Abstract] [Full Text] [PDF]

				P. Fesler, A. Pagnamenta, J-L. Vachiery, S. Brimioulle, S. Abdel Kafi, A. Boonstra, M. Delcroix, R.N. Channick, L.J. Rubin, and R. Naeije Single arterial occlusion to locate resistance in patients with pulmonary hypertension Eur. Respir. J., January 1, 2003; 21(1): 31 - 36. [Abstract] [Full Text] [PDF]

				A. Sablotzki, E. Czeslick, S. Schubert, I. Friedrich, J. Muhling, M. G. Dehne, S. Grond, and T. Hentschel Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension: [L'iloprost ameliore l'hemodynamique chez des malades souffrant d'insuffisance cardiaque chronique et d'hypertension arterielle pulmonaire] Can J Anesth, December 1, 2002; 49(10): 1076 - 1080. [Abstract] [Full Text] [PDF]

				D. Chemla, V. Castelain, P. Herve, Y. Lecarpentier, and S. Brimioulle Haemodynamic evaluation of pulmonary hypertension Eur. Respir. J., November 1, 2002; 20(5): 1314 - 1331. [Abstract] [Full Text] [PDF]

				A. Sablotzki, T. Hentschel, E. Gruenig, S. Schubert, I. Friedrich, J. Muhling, M. G. Dehne, and E. Czeslick Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance Eur. J. Cardiothorac. Surg., November 1, 2002; 22(5): 746 - 752. [Abstract] [Full Text] [PDF]

				O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, P. Herve, M. Rainisio, and G.e. Simonneau Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival J. Am. Coll. Cardiol., August 21, 2002; 40(4): 780 - 788. [Abstract] [Full Text] [PDF]

				B.H. Jiang, J. Maruyama, A. Yokochi, H. Amano, Y. Mitani, and K. Maruyama Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes Eur. Respir. J., July 1, 2002; 20(1): 52 - 58. [Abstract] [Full Text] [PDF]

				H. A. Ghofrani, R. Wiedemann, F. Rose, H. Olschewski, R. T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension Ann Intern Med, April 2, 2002; 136(7): 515 - 522. [Abstract] [Full Text] [PDF]

				H.A. Ghofrani, R. Wiedemann, F. Rose, N. Weissmann, R.T. Schermuly, K. Quanz, F. Grimminger, W. Seeger, and H. Olschewski Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders Eur. Respir. J., April 1, 2002; 19(4): 664 - 671. [Abstract] [Full Text] [PDF]

				R. D'Souza, R.J. MacFadyen, F. Kerr, A. Peacock, and M.M. Steven Lessons to be learned: a case study approach A case study of the temporal onset of pulmonary hypertension with pre-existent cirrhotic portal hypertension The Journal of the Royal Society for the Promotion of Health, December 1, 2001; 121(4): 257 - 261. [Abstract] [PDF]

				W Budts, N Van Pelt, H Gillyns, M Gewillig, F Van de Werf, and S Janssens Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome Heart, November 1, 2001; 86(5): 553 - 558. [Abstract] [Full Text] [PDF]

				J.-L. CRACOWSKI, C. CRACOWSKI, G. BESSARD, J.-L. PEPIN, J. BESSARD, C. SCHWEBEL, F. STANKE-LABESQUE, and C. PISON Increased Lipid Peroxidation in Patients with Pulmonary Hypertension Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 1038 - 1042. [Abstract] [Full Text] [PDF]

				V. Castelain, P. Herve, Y. Lecarpentier, P. Duroux, G. Simonneau, and D. Chemla Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1085 - 1092. [Abstract] [Full Text] [PDF]

				B. A. Cockrill, R. M. Kacmarek, M. A. Fifer, L. M. Bigatello, L. C. Ginns, W. M. Zapol, and M. J. Semigran Comparison of the Effects of Nitric Oxide, Nitroprusside, and Nifedipine on Hemodynamics and Right Ventricular Contractility in Patients With Chronic Pulmonary Hypertension Chest, January 1, 2001; 119(1): 128 - 136. [Abstract] [Full Text] [PDF]

				S. Gaine Pulmonary Hypertension JAMA, December 27, 2000; 284(24): 3160 - 3168. [Abstract] [Full Text] [PDF]

				R. A. Krasuski, J. J. Warner, A. Wang, J. K. Harrison, V. F. Tapson, and T. M. Bashore Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2204 - 2211. [Abstract] [Full Text] [PDF]

				Y. M. Smulders Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction Cardiovasc Res, October 1, 2000; 48(1): 23 - 33. [Abstract] [Full Text] [PDF]

				D. J. Williamson, L. L. Wallman, R. Jones, A. M. Keogh, F. Scroope, BEd, R. Penny, C. Weber, and P. S. Macdonald Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary Hypertension Circulation, July 25, 2000; 102(4): 411 - 418. [Abstract] [Full Text] [PDF]

				H. Imanaka, H. Miyano, M. Takeuchi, K. Kumon, and M. Ando Effects of Nitric Oxide Inhalation After Pulmonary Thromboendarterectomy for Chronic Pulmonary Thromboembolism Chest, July 1, 2000; 118(1): 39 - 46. [Abstract] [Full Text] [PDF]

				J. CHRISTENSON, A. LAVOIE, M. O'CONNOR, S. BHORADE, A. POHLMAN, and J. B. HALL The Incidence and Pathogenesis of Cardiopulmonary Deterioration after Abrupt Withdrawal of Inhaled Nitric Oxide Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1443 - 1449. [Abstract] [Full Text]

				H. Olschewski, H. A. Ghofrani, T. Schmehl, J. Winkler, H. Wilkens, M. M. Hoper, J. Behr, F.-X. Kleber, W. Seeger, and for the German PPH Study Group* Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial Ann Intern Med, March 21, 2000; 132(6): 435 - 443. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, H. Olschewski, H. A. Ghofrani, H. Wilkens, J. Winkler, M. M. Borst, J. Niedermeyer, H. Fabel, W. Seeger, and the German PPH Study Group A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension J. Am. Coll. Cardiol., January 1, 2000; 35(1): 176 - 182. [Abstract] [Full Text] [PDF]

				M. FARTOUKH, M. HUMBERT, F. CAPRON, S. MAÎTRE, F. PARENT, C. LE GALL, O. SITBON, P. HERVÉ, P. DUROUX, and G. SIMONNEAU Severe Pulmonary Hypertension in Histiocytosis X Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 216 - 223. [Abstract] [Full Text]

				M. J. Ricciardi, E. Bossone, D. S. Bach, W. F. Armstrong, and M. Rubenfire Echocardiographic Predictors of an Adverse Response to a Nifedipine Trial in Primary Pulmonary Hypertension: Diminished Left Ventricular Size and Leftward Ventricular Septal Bowing Chest, November 1, 1999; 116(5): 1218 - 1223. [Abstract] [Full Text] [PDF]

				E. R. Schmid, C. Burki, M. H. C. Engel, D. Schmidlin, M. Tornic, and B. Seifert Inhaled Nitric Oxide Versus Intravenous Vasodilators in Severe Pulmonary Hypertension After Cardiac Surgery Anesth. Analg., November 1, 1999; 89(5): 1108 - 1108. [Abstract] [Full Text] [PDF]

				C. S Hayward, R. P Kelly, and P. S Macdonald Inhaled nitric oxide in cardiology practice Cardiovasc Res, August 15, 1999; 43(3): 628 - 638. [Abstract] [Full Text] [PDF]

				H. OLSCHEWSKI, H. ARDESCHIR GHOFRANI, D. WALMRATH, R. SCHERMULY, B. TEMMESFELD-WOLLBRÜCK, F. GRIMMINGER, and W. SEEGER Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 600 - 607. [Abstract] [Full Text]

				M. Aranda, K. K. Bradford, and R. G. Pearl Combined Therapy with Inhaled Nitric Oxide and Intravenous Vasodilators During Acute and Chronic Experimental Pulmonary Hypertension Anesth. Analg., July 1, 1999; 89(1): 152 - 152. [Abstract] [Full Text] [PDF]

				C. M. Hart Nitric Oxide in Adult Lung Disease Chest, May 1, 1999; 115(5): 1407 - 1417. [Abstract] [Full Text] [PDF]

				O. Sanchez, M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary hypertension secondary to connective tissue diseases Thorax, March 1, 1999; 54(3): 273 - 277. [Full Text]

				S. BHORADE, J. CHRISTENSON, M. O'CONNOR, A. LAVOIE, A. POHLMAN, and J. B. HALL Response to Inhaled Nitric Oxide in Patients with Acute Right Heart Syndrome Am. J. Respir. Crit. Care Med., February 1, 1999; 159(2): 571 - 579. [Abstract] [Full Text]

				M. J. Ricciardi, B. P. Knight, F. J. Martinez, and M. Rubenfire Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine J. Am. Coll. Cardiol., October 1, 1998; 32(4): 1068 - 1073. [Abstract] [Full Text] [PDF]

				M. HUMBERT, S. M. TRE, F. CAPRON, B. RAIN, D. MUSSET, and G. SIMONNEAU Pulmonary Edema Complicating Continuous Intravenous Prostacyclin in Pulmonary Capillary Hemangiomatosis Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1681 - 1685. [Abstract] [Full Text]

				L. J. Rubin Primary Pulmonary Hypertension N. Engl. J. Med., January 9, 1997; 336(2): 111 - 117. [Full Text] [PDF]

				D.J. Williamson, C. Hayward, P. Rogers, L.L. Wallman, A.D. Sturgess, R. Penny, and P.S. Macdonald Acute Hemodynamic Responses to Inhaled Nitric Oxide in Patients With Limited Scleroderma and Isolated Pulmonary Hypertension Circulation, August 1, 1996; 94(3): 477 - 482. [Abstract] [Full Text]

				D. Royston Surgery with cardiopulmonary bypass and pulmonary inflammatory responses Perfusion, May 1, 1996; 11(3): 213 - 219. [PDF]